Last reviewed · How we verify
NCT06294067: DRI-DHA
A Dose Response Investigation of Docosahexaenoic Acid (DHA)
Phase 1 trial testing docosahexaenoic acid (DHA) in Nutrition, Healthy in 72 participants. Completed in 26 March 2025.
26 February 2025
Quick facts
| Lead sponsor | University of Toronto |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 72 |
| Start date | 26 February 2024 |
| Primary completion | 26 February 2025 |
| Estimated completion | 26 March 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- docosahexaenoic acid (DHA) — full drug profile →
- soybean oil placebo
Conditions studied
- Nutrition, Healthy — all drugs for Nutrition, Healthy →
Sponsor
University of Toronto
Who can join
Adults 18 to 50, any sex, with Nutrition, Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid (n-3 PUFA), commonly consumed from fish, that regulates many critical functions within the body including the brain, eye, and heart. While the metabolic precursor to DHA, alpha-linolenic acid (ALA) is considered nutritionally essential and has a set Dietary Reference Intake (DRI), DHA has not yet been deemed essential and does not have a set DRI. Currently, research suggests an intake range of dietary DHA to be anywhere from 0 to over 500mg/d. The aim of our study is to further investigate a feedback mechanism or accumulation that occurs with eicosapentaenoic acid (EPA) as a result of increased dietary DHA to provide insight for potential Recommended Dietary Intake (RDI) values. Hypothesis: The dietary DHA dose at which blood EPA levels increase is the point at which elongation slows, indicating a significant negative feedback pathway is present. Objectives: 1: To determine the dose-response for DHA to increase blood EPA levels in a mixed vegetarian and vegan population. 2: Investigate the DHA dose and time at dose that increases EPA using natural abundance delta carbon-13 (δ13C) as a tracer. 3: To measure DHA turnover and loss rates. 4: Provide data for exploratory analyses related to PUFA metabolism and the effect of DHA on disease related biomarkers. Method: During an 8-week trial, 72 healthy vegan or vegetarian males and females (18-50 years) will be supplemented with 1 of 6 algal-oil based DHA doses: 0, 100, 200, 400, 800 or 1000 mg/d. Blood will be collected at days 0, 3, 7, 14, 28 and 56 and will be analyzed for changes in blood EPA levels as the primary outcome and plasma δ13C EPA signature as the secondary outcome. Significance: Investigating this negative feedback pathway is of great importance in providing evidence to support n-3 PUFA DRIs. EPA and DHA are ecologically sensitive with their major source coming from unsustainably farmed fish stocks and having a set DRI may help to limit the overconsumption of these nutrients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06294067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nutrition, Healthy
Currently open trials in the same condition.
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06897982 — Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center · NA · recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
- NCT07054294 — Total Energy Expenditure Across the Life Course in Low-and Middle-Income Countries -- Chinese Children · recruiting
- NCT07056504 — Technologies and Systems for Assessing Human Energy Metabolism and Nutritional Rehabilitation · recruiting
Other University of Toronto trials
Trials by the same sponsor.
- NCT07184255 — Animated Video Education for Retinal Surgery · NA · not yet recruiting
- NCT07259434 — Time Restricted Eating in Survivors Trial 2.0 · NA · not yet recruiting
- NCT07486050 — The Impact of Social Worker Referrals on Diabetes and Loneliness · NA · active not recruiting
- NCT07268729 — Investigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders · not yet recruiting
- NCT07317921 — Validating IAAO for Muscle Outcomes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06294067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Toronto
- Last refreshed: 3 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06294067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing